Tazemetostat Approval Status
FDA Approved: No
Generic name: tazemetostat
Company: Epizyme, Inc.
Treatment for: Epithelioid Sarcoma
Tazemetostat is an oral, first-in-class, EZH2 inhibitor in development for the treatment of patients with metastatic or locally advanced epithelioid sarcoma.
Development Status and FDA Approval Process for tazemetostat
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.